You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tyrosine kinase inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Breast Cancer Trial in Guangzhou (Take probiotics)

Recruiting
  • Breast Cancer
  • Take probiotics
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 6, 2023

HRQOL in Locally Advanced Thyroid Carcinoma

Recruiting
  • Thyroid Cancer
  • +2 more
  • Tyrosine kinase inhibitor drugs.
  • Fuzhou, Fujian, China
    Road Fuma No.420
Apr 11, 2023

Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

Completed
  • Gastrointestinal Stromal Tumors (GISTs)
  • Imatinib Mesylate
  • Seoul, Korea, Republic of
    Asan Medical Center
Dec 30, 2022

Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Nov 28, 2022

Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

Active, not recruiting
  • Multiple Sclerosis
  • tolebrutinib 60mg
  • tolebrutinib 120mg
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

Not yet recruiting
  • Tyrosine Kinase Inhibitor
  • +2 more
    • Taipei, Taiwan
      National Taiwan University Hospital
    Feb 17, 2022

    Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Philadelphia Chromosome-Positive
    • Blinatumomab
    • +3 more
    • New York, New York
    • +1 more
    Nov 10, 2022

    Metabolic Alternation and Clinicohematological Characteristic in

    Not yet recruiting
    • CML, Chronic Phase
    • Tyrosine kinase inhibitor
    • (no location specified)
    Nov 6, 2023

    Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • East Melbourne, Victoria, Australia
    • +7 more
    Jan 20, 2023

    High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

    Recruiting
    • High-Risk Localized Soft Tissue Sarcoma
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 20, 2023

    Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

    Active, not recruiting
    • Neoplasm
    • Beijing, China
    • +5 more
    Jan 31, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    CNS Lymphoma Trial in Petah Tikva (Imbruvica)

    Recruiting
    • Central Nervous System Lymphoma
    • Petah Tikva, Israel
      Hematology Institute
    May 9, 2022

    GastroEsophageal Cancer, Gastric Cancer Trial in New York (Lenvatinib, Pembrolizumab)

    Recruiting
    • GastroEsophageal Cancer
    • Gastric Cancer
    • New York, New York
    • +1 more
    Aug 12, 2022

    Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Tumor Trial in Buffalo, Columbus (Laboratory Biomarker Analysis,

    Active, not recruiting
    Has Results
    • Carcinoid Tumor
    • +2 more
    • Laboratory Biomarker Analysis
    • +3 more
    • Buffalo, New York
    • +1 more
    Nov 8, 2022

    Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
      • Rotterdam, Netherlands
        Erasmus MC
      Feb 2, 2022

      Chronic Leukemia Trial in France (Additional biological samples)

      Active, not recruiting
      • Chronic Leukemia
      • Additional biological samples
      • Besançon, France
      • +3 more
      May 31, 2022

      Diabetic Macular Edema Trial (EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)

      Not yet recruiting
      • Diabetic Macular Edema
      • (no location specified)
      Oct 19, 2023

      Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer Trial in Duarte (other, dietary supplement, drug)

      Active, not recruiting
      • Diarrhea
      • +2 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Duarte, California
        City of Hope Medical Center
      Jun 7, 2022

      Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

      Recruiting
      • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
      • Topical Timolol
      • Hong Kong, Hong Kong
        Queen Mary Hospital
      Nov 14, 2023

      Resistance to Tyrosine Kinase Inhibitor Osimertinib and

      Recruiting
      • Lung Cancer
      • Blood Samples
      • Lorient, France
      • +3 more
      Apr 26, 2022

      Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia Trial in Philadelphia (Text

      Recruiting
      • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      • Chronic Phase Chronic Myelogenous Leukemia
      • Text Message-Based Navigation Intervention
      • Survey Administration
      • Philadelphia, Pennsylvania
        Sidney Kimmel Cancer Center at Thomas Jefferson University
      Apr 7, 2022